Giuliano R A, Verpooten G A, De Broe M E
Antimicrob Agents Chemother. 1986 Sep;30(3):385-9. doi: 10.1128/AAC.30.3.385.
Beads of gentamicin-polymethylmethacrylate (Septopal), each containing 4.5 mg of gentamicin base, were implanted intraperitoneally in rats. Each rat received one bead. Serum levels and urinary excretion of gentamicin were maximal in the first day of treatment (0.6 micrograms/ml in serum 3 h after implantation of the bead and 525 micrograms per 24-h urine sample) and decreased thereafter. Kidney cortical concentrations of gentamicin progressively increased and peaked after 4 days, reaching 117 micrograms/g. Tissue levels decreased thereafter in spite of the persistence of the drug in urine, and this occurred in the absence of cell damage leading to cell death. Release of gentamicin from intact proximal tubular cells, despite continuous uptake, prevented intracellular drug concentrations from reaching a nephrotoxic level. This experimental study provides a rational basis for the previous clinical observation that nephrotoxicity due to treatment with gentamicin-polymethylmethacrylate beads is improbable.
将含4.5毫克庆大霉素碱的庆大霉素-聚甲基丙烯酸甲酯珠(Septopal)植入大鼠腹腔内,每只大鼠植入一粒珠子。庆大霉素的血清水平和尿排泄量在治疗第一天最高(植入珠子3小时后血清中为0.6微克/毫升,每24小时尿样中为525微克),此后下降。庆大霉素的肾皮质浓度逐渐升高,并在4天后达到峰值,为117微克/克。尽管尿液中药物持续存在,但此后组织水平下降,且这一过程发生在无导致细胞死亡的细胞损伤情况下。尽管近端肾小管细胞持续摄取庆大霉素,但完整的近端肾小管细胞释放庆大霉素可防止细胞内药物浓度达到肾毒性水平。这项实验研究为先前的临床观察提供了合理依据,即使用庆大霉素-聚甲基丙烯酸甲酯珠治疗导致肾毒性的可能性不大。